A Phase 1 SARS-CoV-2 Vaccine Study to Assess the Safety and Tolerability of GRT-R912, GRT-R914, and GRT-R918 Administered as Prime and/or Boost in Healthy Adult Participants and People Living With HIV
Gritstone bio, Inc. is advancing its portfolio of samRNA vaccines (GRT-R912, GRT-R914, GRT-R918) aimed at providing a robust immune response against SARS-CoV-2, particularly in diverse populations including people living with HIV. The completion of this Phase 1 trial indicates progress towards potential commercialization, especially in markets with high COVID-19 prevalence and a need for effective booster vaccines. The focus on both naive and previously vaccinated individuals enhances the product's marketability. Competitive analysis suggests that while several mRNA vaccines are already available, Gritstone's unique approach may offer differentiated immune responses, potentially positioning it favorably against established players. Diligence should focus on safety data and the ability to demonstrate superior efficacy in varied populations.
Indication: COVID-19
Modality: RNA therapy
Target: Self-amplifying messenger RNA (samRNA) vaccines targeting SARS-CoV-2 Spike protein and T cell epitopes.
Sponsor: Gritstone bio, Inc.
Source URL: ClinicalTrials.gov
Source updated: Detailed source ingestion pending
Ingested: Jun 23, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by target_normalized: Self-amplifying messenger RNA (samRNA) vaccines targeting SARS-CoV-2 Spike protein and T cell epitopes.
View original source fields
Condition raw: COVID-19, SARS-CoV-2
Condition normalized: COVID-19, SARS-CoV-2
Modality raw: RNA therapy
Modality normalized: RNA therapy
Target raw: Self-amplifying messenger RNA (samRNA) vaccines targeting SARS-CoV-2 Spike protein and T cell epitopes.
Target normalized: Self-amplifying messenger RNA (samRNA) vaccines targeting SARS-CoV-2 Spike protein and T cell epitopes.